Previous 10 | Next 10 |
home / stock / seovf / seovf news
2024-03-27 17:08:02 ET © 2020 www.B-TV.com . All Rights Reserved. Regenerative medicine solution that could be used for diabetes and other chronic diseases Sernova is a regenerative medicine therapeutics company. They are developing therapeutics platform technologies ...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - March 11, 2024 – Sernova Corp. (TSX:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage company focused on providing regenerative medicine therapeutics to patients with chronic conditions, today announ...
2024-01-29 07:21:15 ET More on Sernova Historical earnings data for Sernova Financial information for Sernova Read the full article on Seeking Alpha For further details see: Sernova reports anticipated 2024 milestones
(TheNewswire) Recently completed recruitment of all 7 patients in Cohort 2 Anticipates additional data from Cohort 2 of Phase 1/2 clinical trial evaluating its enhanced 10-channel Cell Pouch in patients with type 1 diabetes (T1D) in Q1/24 Expects to report precli...
Koss Corporation (KOSS) is expected to report for Q2 2024 Waterstone Financial Inc. (WSBF) is expected to report for Q4 2023 Silver Bull Resources Inc (SVBL) is expected to report for quarter end 2023-10-31 Xcel Energy Inc. (XEL) is expected to report $0.85 for Q4 2023 Sodexo ADR ...
2023-11-27 15:06:31 ET More on Sernova Historical earnings data for Sernova Financial information for Sernova For further details see: Sernova gets FDA orphan drug, rare pediatric designations for hemophilia A
LONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) ...
LONDON, Ontario and WINDHAM COUNTY, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced an update on its conformal coating immune protection technology program, that is used in co...
All six patients in the first cohort (Cohort A) were successfully implanted with the 8-channel Cell Pouch System with post-transplant follow-up periods ranging from 6 months to 3.5 years; 5 of 6 patients in Cohort A discontinued insulin therapy (insulin independent) following islet transplant...
Dr. Piotr Witkowski presenting new data from ongoing Phase 1/2 clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D) Dr. Alice Tomei presenting preclinical data on transplantation of conformal coated islet cells in pre-vascularized Cell Pouch LONDO...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) To date Sernova reports 7 patients in its Phase I/II type 1 diabetes clinical trial achieved freedom from insulin injections and demonstrate blood sugar control in the non- diabetic range (HbA1c 6.5%); 6 patients have reached between 5.5 and 50 months o...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – June 12, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatmen...
Orbital Infrastructure Group Inc. (OIGBQ) is expected to report for Q1 2024 OFS Credit Company Inc. (OCCI) is expected to report for Q2 2024 KBC Groupe NV ADR (KBCSY) is expected to report for Q1 2024 Daikin Industries Ltd ADR (DKILY) is expected to report $0.11 for Q4 2024 Invita...